Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
MRKR Marker Therapeutics
0.321
+0.014+4.56%
Post Mkt Price
0.326
+0.004+1.34%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Investing cash flow
Cash flow from continuing investing activities
95.03% -99.37K -567.36% -2.27M -455.88% -2.45M 69.97% -3.13M
Net PPE purchase and sale
95.03% -99.37K -567.36% -2.27M -455.88% -2.45M 69.97% -3.13M
Cash from discontinued investing activities
Investing cash flow
95.03% -99.37K -567.36% -2.27M -455.88% -2.45M 69.97% -3.13M
Financing cash flow
Cash flow from continuing financing activities
0 163.10% 63.57K 0 680.22% 52.56M
Net common stock issuance
-- 0 161.23% 63.57K -- 0 749.54% 52.55M
Proceeds from stock option exercised by employees
-- 0 -- -- -- -- -99.44% 3.09K
Cash from discontinued financing activities
Financing cash flow
-- 0 163.10% 63.57K -- 0 680.22% 52.56M
Net cash flow
Beginning cash position
-54.87% 25.82M -55.32% 28.82M 103.71% 43.5M -51.37% 21.35M
Current changes in cash
9.05% -7.75M 58.86% -3M -134.01% -14.68M 198.20% 22.14M
End cash Position
-62.89% 18.08M -54.87% 25.82M -55.32% 28.82M 103.71% 43.5M
Free cash flow
9.05% -7.75M 57.40% -3.06M -54.49% -14.68M -3.84% -30.41M
Investing cash flow
Cash flow from continuing investing activities
95.03% -99.37K -567.36% -2.27M -455.88% -2.45M 69.97% -3.13M
Net PPE purchase and sale
95.03% -99.37K -567.36% -2.27M -455.88% -2.45M 69.97% -3.13M
Cash from discontinued investing activities
Investing cash flow
95.03% -99.37K -567.36% -2.27M -455.88% -2.45M 69.97% -3.13M
Financing cash flow
Cash flow from continuing financing activities
0 163.10% 63.57K 0 680.22% 52.56M
Net common stock issuance
-- 0 161.23% 63.57K -- 0 749.54% 52.55M
Proceeds from stock option exercised by employees
-- 0 -- -- -- -- -99.44% 3.09K
Cash from discontinued financing activities
Financing cash flow
-- 0 163.10% 63.57K -- 0 680.22% 52.56M
Net cash flow
Beginning cash position
-54.87% 25.82M -55.32% 28.82M 103.71% 43.5M -51.37% 21.35M
Current changes in cash
9.05% -7.75M 58.86% -3M -134.01% -14.68M 198.20% 22.14M
End cash Position
-62.89% 18.08M -54.87% 25.82M -55.32% 28.82M 103.71% 43.5M
Free cash flow
9.05% -7.75M 57.40% -3.06M -54.49% -14.68M -3.84% -30.41M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion with Explanation

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
CEO: Mr. Peter L. Hoang
Market: NASDAQ
Listing Date: 11/07/2016
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist